Toward the definition of immunosuppressive regimens with antitumor activity

Transplantation Proceedings

Volumn 37, Issue 5, 2005, Pages 2144-2147

  Casadio, F ^a   Croci, S ^a   D'Errico Grigioni, A ^b   Corti, B ^b   Grigioni, W F ^b   Landuzzi, L ^a   Lollini, P L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; LEFLUNOMIDE; MYCOPHENOLIC ACID; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RISK; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR CELL LINE; UMBILICAL VEIN;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; JURKAT CELLS; LIVER NEOPLASMS; MYCOPHENOLIC ACID; RHABDOMYOSARCOMA; SIROLIMUS;

EID: 21844452148     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.03.089     Document Type: Article

References (18)

1. J. Fricker New UK guidelines for use of immunosuppressive agents Lancet Oncol 5 2004 643
2. A.G. Sheil Cancer in immune-suppressed organ transplant recipients aetiology and evolution Transplant Proc 30 1998 2055
3. G.E. Koehl, J. Andrassy, M. Guba Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice Transplantation 77 2004 1319
4. D.J. Boffa, F. Luan, D. Thomas Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer Clin Cancer Res 10 2004 293
5. F.L. Luan, R. Ding, V.K. Sharma Rapamycin is an effective inhibitor of human renal cancer metastasis Kidney Int 63 2003 917
6. S. Croci, L. Landuzzi, A. Astolfi Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells Cancer Res 64 2004 1730
7. X. Xu, J. Shen, J.W. Mall In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide mechanisms of action Biochem Pharmacol 58 1999 1405
8. A.C. Allison, E.M. Eugui Mycophenolate mofetil and its mechanisms of action Immunopharmacology 47 2000 85
9. G. Schumacher, M. Oidtmann, S. Rosewicz Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth Transplant Proc 34 2002 1392
10. N. Andre, B. Roquelaure, J. Conrath Molecular effects of cyclosporine and oncogenesis a new model Med Hypotheses 63 2004 647
11. M. Hojo, T. Morimoto, M. Maluccio Cyclosporine induces cancer progression by a cell- autonomous mechanism Nature 397 1999 530
12. W.C. Noh, W.H. Mondesire, J. Peng Determinants of rapamycin sensitivity in breast cancer cells Clin Cancer Res 10 2004 1013
13. M.A. Bjornsti, P.J. Houghton The TOR pathway a target for cancer therapy Nat Rev Cancer 4 2004 335
14. M. Guba, P. von Breitenbuch, M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis involvement of vascular endothelial growth factor Nat Med 8 2002 128
15. R.J. Tressler, L.J. Garvin, D.L. Slate Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo Int J Cancer 57 1994 568
16. T.J. Franklin, V. Jacobs, G. Jones Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells Cancer Res 56 1996 984
17. J.W. Mall, J.A. Myers, X. Xu Leflunomide reduces the angiogenesis score and tumor growth of subcutaneously implanted colon carcinoma cells in the mouse model Chirurg 73 2002 716
18. M. Raab, H. Daxecker, A. Karimi In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells Clin Chim Acta 310 2001 89